/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style

pb-0

INDIVIOR PLC

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$34.7 0.0006(0.06%) INDV at 04 Dec 2025 04:35 PM Drug Manufacturers - Specialty & Generic

Lowest Today 33.92

Highest Today 34.615

Today’s Open 34.13

Prev. Close 34

52 Week High 34.64

52 Week Low 7.62

Day’s Range: Low 33.92 High 34.615

52-Week Range: Low 7.62 High 34.64

Institutional Holdings

Market Status

Strong Buy: 5

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 4250.83 M

PB Ratio 145.2492

PE Ratio 34.3434

Enterprise Value 4111.82 M

Total Assets 1319.00 M

Volume 1695644

Company Financials

Annual Revenue FY23:1042000000 1042.0M, FY22:901000000 901.0M, FY21:791000000 791.0M, FY20:647000000 647.0M, FY19:785000000 785.0M

Annual Profit FY23:863000000 863.0M, FY22:742000000 742.0M, FY21:664000000 664.0M, FY20:550000000 550.0M, FY19:645000000 645.0M

Annual Net worth FY23:-235000000 -235.0M, FY22:-53000000 -53.0M, FY21:205000000 205.0M, FY20:-148000000 -148.0M, FY19:134000000 134.0M

Quarterly Revenue Q3/2025:314000000 314.0M, Q2/2025:302000000 302.0M, Q1/2025:266000000 266.0M, Q3/2024:307000000 307.0M, Q2/2024:299607713 299.6M

Quarterly Profit Q3/2025:230000000 230.0M, Q2/2025:250000000 250.0M, Q1/2025:222000000 222.0M, Q3/2024:238000000 238.0M, Q2/2024:183371945 183.4M

Quarterly Net worth Q3/2025:42000000 42.0M, Q2/2025:18000000 18.0M, Q1/2025:47000000 47.0M, Q3/2024:4000000 4.0M, Q2/2024:-107217475 -107.2M

Fund house & investment objective

Company Information Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). The company also offers OPVEE nasal spray for opioid overdose reversal. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Organisation Drug Manufacturers - Specialty & Generic

Employees 1030

Industry Drug Manufacturers - Specialty & Generic

CEO Mr. Joseph J. Ciaffoni

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations

Left

Get expert assistance for portfolio management

Right

style

align-center,button-arrow